Editorial
doi: 10.1007/s00259-013-2415-x.
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine
- PMID: 23619939
- DOI: 10.1007/s00259-013-2415-x
Item in Clipboard
Editorial
Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine
Eur J Nucl Med Mol Imaging.
2013 Jul.
No abstract available
Comment on
-
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.J Nucl Med. 2013 Mar;54(3):476-90. doi: 10.2967/jnumed.113.120618. Epub 2013 Jan 28. J Nucl Med. 2013. PMID: 23359661 Review.
Similar articles
-
Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.J Nucl Med. 2013 Mar;54(3):476-90. doi: 10.2967/jnumed.113.120618. Epub 2013 Jan 28. J Nucl Med. 2013. PMID: 23359661 Review.
-
[German Society of Nuclear Medicine procedure guideline on beta-amyloid brain PET imaging].Nuklearmedizin. 2016 Aug 5;55(4):129-37. doi: 10.3413/Nukmed-0816-16-04. Epub 2016 Apr 15. Nuklearmedizin. 2016. PMID: 27080914 German.
-
[Amyloid positron-emission-tomography with [18 F]-florbetaben in the diagnostic workup of dementia patients].Nervenarzt. 2017 Feb;88(2):156-161. doi: 10.1007/s00115-016-0249-z. Nervenarzt. 2017. PMID: 27913818 German.
-
Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1702-14. doi: 10.1007/s00259-011-1821-1. Epub 2011 May 6. Eur J Nucl Med Mol Imaging. 2011. PMID: 21547601 Clinical Trial.
-
Appropriate use criteria for dementia amyloid imaging in Switzerland - mini-review and statement on behalf of the Swiss Society of Nuclear Medicine and the Swiss Memory Clinics.Nuklearmedizin. 2021 Feb;60(1):7-9. doi: 10.1055/a-1277-6014. Epub 2020 Oct 20. Nuklearmedizin. 2021. PMID: 33080626 Review. English.
Cited by
-
Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice.Neurol Sci. 2015 Jun;36(6):1075-81. doi: 10.1007/s10072-015-2079-3. Neurol Sci. 2015. PMID: 25616445
-
Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1700-9. doi: 10.1007/s00259-016-3353-1. Epub 2016 Mar 30. Eur J Nucl Med Mol Imaging. 2016. PMID: 27026271
-
Amyloid imaging in atypical dementia.CMAJ. 2014 Jun 10;186(9):695. doi: 10.1503/cmaj.131158. Epub 2014 Jan 20. CMAJ. 2014. PMID: 24446462 Free PMC article. No abstract available.
-
Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo.Eur J Nucl Med Mol Imaging. 2014 May;41(5):836-43. doi: 10.1007/s00259-013-2656-8. Epub 2013 Dec 19. Eur J Nucl Med Mol Imaging. 2014. PMID: 24435769 Free PMC article.
-
Impact of amyloid-PET in daily clinical management of patients with cognitive impairment fulfilling appropriate use criteria.Medicine (Baltimore). 2019 Jul;98(29):e16509. doi: 10.1097/MD.0000000000016509. Medicine (Baltimore). 2019. PMID: 31335725 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
